it seems there are 2 other bits on info that are good for AGX hidden in this announcement - they can now take Thrombowview to full commercialisation without any extra capital (no dilution) and the cash at bank on June 30 was 9.5m - an increase of 1.5m I think from last year - given they would have spent 3-5m on R&D (my guess) and they suspended sales to the US for the last month or so of the year they must be producing serious cash.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $2.256K | 1.127M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 46361991 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 6600521 | 9 |
View Market Depth
| Last trade - 11.49am 12/08/2025 (20 minute delay) ? |
| CT1 (ASX) Chart |